Amarin Corp Q2 Sales $42.211M Miss $44.550M Estimate

argenx Meets Primary Endpoint in Phase II Celiac Disease Study

argenx announced positive phase II results for FB102, an investigational therapy for celiac disease, meeting its primary endpoint with significant improvements in intestinal tissue measures versus placebo and no new safety signals. The company plans to advance FB102 into late-stage development and evaluate it for other autoimmune conditions. However, the stock declined nearly 12% following a separate announcement that argenx discontinued its phase III UNITY study for Vyvgart Hytrulo in Sjögren's disease.

Why Is Tango Therapeutics (TNGX) Down 6.2% Since Last Earnings Report?

Tango Therapeutics (TNGX) stock has declined 6.2% since its Q2 2026 earnings report, underperforming the S&P 500. The company reported a wider-than-expected loss of 37 cents per share due to higher operating expenses, with R&D expenses up 13% and G&A expenses nearly doubling. Collaboration revenues dropped to zero from $3.2 million year-over-year following the conclusion of its Gilead partnership. Analyst estimates have shifted downward by 10.16% in the past month, and the stock carries a Zacks Rank #3 (Hold) with poor VGM scores across growth, momentum, and value metrics.

Amarin Says REDUCE-IT Post Hoc Analysis Showed About 30% Relative Risk Reduction In Major Adverse Cardiovascular Events Among Patients On Icosapent Ethyl At Least 1.5 Years; Hazard Ratio Of 0.73 Persisted After Discontinuation

JP Morgan Reinstates Underweight on Amarin Corp, Announces $13 Price Target

JP Morgan analyst Jessica Fye reinstates Amarin Corp (NASDAQ:AMRN) with a Underweight and announces $13 price target.